2015 Oct 15 version: RCEP IP Chapter
Attached here (in docx format) is the October 15, 2015 version of the draft intellectual property right chapter for the proposed Regional Comprehensive Economic Partnership (RCEP).
Author: KEI Staff
2016: NIH licenses on Boron Neutron patents, to Beijing Lanyears Communication
2016: NIH license on patents on 5T4 Antibodies for cancer treatment, diagnostics, to Ovensa, located in Ontario, Canada
(More on government funded inventions here. Other KEI comments on NIH licenses are found here.) These are the April 17, 2016 KEI comments on the NIH proposed exclusive license to Ovensa, for patents on 5T4 antibodies for cancer treatment and… Continue Reading
KEI comment on WIPO report on patents landscape for the WHO essential medicines list
This is a comment on the WIPO- commissioned report on the patent landscape for the WHO essential medicines list, published on April 11th, 2016. The report is titled: Patent-based Analysis of the World Health Organization’s 2013 Model List of Essential Medicines, by Reed F. Beall and Amir Attaran, both at the University of Ottawa, Canada. This is is the third collaboration between WIPO’s Thomas (Tom) Bombelles (Head, Global Health, WIPO) and Attaran on the same topic — the patenting of medicines in developing countries.
2016: Objection to exclusive license to AestasRx Inc.
(More on government funded inventions here. Other KEI comments on NIH licenses are found here.) Susan Ano, Ph.D., NINDS Technology Transfer, 31 Center Drive, Suite 8A52, MSC2540 Bethesda, MD 20892; Telephone: (301) 435-5515; anos@mail.nih.gov Dear Dr. Ano, I am writing to express… Continue Reading
2016: Midissia Therapeutics license of NIH owned breast and prostate cancer vaccine patents
(More on government funded inventions here. Other KEI comments on NIH licenses are found here.) Sabarni K. Chatterjee, Ph.D., M.B.A. Senior Licensing and Patenting Manager, NCI Technology Transfer Center, 9609 Medical Center Drive, RM 1E530 MSC 9702, Bethesda, MD 20892-9702… Continue Reading
2016: AltraTech, KEI comments on NIH proposal for exclusive licenses for vitro diagnostics patents
Other KEI comments on NIH licenses are found here: /nih-licenses
February 22, 2016
Patrick McCue, Ph.D.
Senior Licensing and Patenting Manager
Technology Advancement Office
The National Institutes of Diabetes and Digestive and Kidney Diseases
12A South Drive
Bethesda, MD 20892
via email: patrick.mccue@nih.govDear Dr. McCue:
Knowledge Ecology International joins amicus brief on non-copyrightability of model laws and statutes
Washington, DC — On January 11, 2016, Knowledge Ecology International joined Public Knowledge and the American Library Association in an amicus curiae brief that argued that the contents of model laws, once enacted into statute, cannot be protected by copyright. The brief was filed with the U.S. District Court for the District of Columbia in the case of ASTM International v. Public.Resource.Org.
US ITC notice for public comment, Jan 13, 2016 hearing, and Commission report on the TransPacific Partnership Agreement (TPP)
Here is the US International Trade Commission (USITC) notice for the public hearing, public comments and Commission report on the Trans-Pacific Partnership Agreement (TPP). The deadlines and other requirements for participation may be strictly enforced. Note the ITC anticipates transmitting its report to the President and the Congress on May 18, 2016.
http://www.usitc.gov/secretary/fed_reg_notices/332/tpa_105_001_notice11172015sgl.pdf
Letter from six NGOs to Obama on the WTO LDC patent waiver negotiation
Six NGOs — including Oxfam America, Health GAP, Knowledge Ecology International (KEI), the Union for Affordable Cancer Treatment (UACT), the Young Professionals Chronic Disease Network (YP-CDN), and Public Citizen — sent a letter to President Obama today asking him to publicly express the United States’ “full and unconditional support” for the waiver of World Trade Organization (WTO) drug patent rules for Least Developed Countries (LDCs). Continue Reading